{
  "id": 19728295,
  "title": "Earnings call transcript: Journey Medical narrows loss in Q3 2026 as Emrosi grows",
  "url": "https://urgent.news/2026/11/12/earnings-call-transcript-journey-medical-narrows-loss-in-q3-2026-as",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-12T23:48:21.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-journey-medical-narrows-loss-in-q3-2026-as-emrosi-grows-93CH-5023743"
  },
  "original_language": "en",
  "account": "Journey Medical reported a 8% increase in revenue for the third quarter of 2026, growing to $19 million from $15 million a year earlier. However, the company's GAAP net loss narrowed significantly, dropping from $3.9 million to $1.3 million, or $0.05 per share. Emrosi, the company's rosacea drug, played a major role in the revenue growth, generating $9 million in net revenue and prescriptions rising to around 40,000 for the quarter. The company also reported positive EBITDA for the second straight quarter, with adjusted EBITDA increasing to $3.5 million from $1.4 million. In terms of growth, net product sales rose 11% year over year, outpacing total revenue growth. The main driver of this growth is Emrosi, with the company gaining more than 5,000 unique prescribers, representing about 35.7% of the U.S. dermatology prescriber base. The results indicate that Journey Medical is moving closer to sustained profitability. However, the stock price has declined, closing at $1.99 and falling to $1.96 in after-hours trading. The company still posts a GAAP loss and has a market capitalization of $67 million at current prices. Investors view the stock as potentially undervalued, with an InvestingPro Financial Health Score of 3.43 out of 5, rated as \"GREAT.\"",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}